Risk of Losing Development Information Due to System Failures or Security Breaches
First written in FY2017. 7 of 8 entries say "Restated". Latest entry: FY2023-Q3.
The whole theme swung hardest in 2026: 8 of 36 companies on the "Worse" side.
43 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of loss of development information due to system failures and security breaches. - FY2020RestatedAnnual report
「In the event of a system failure, security breach or similar incident, important information held by the company relating to the pharmaceutical development process may be lost or leaked.」
The company continues to disclose the risk of loss or leakage of development information due to system failures and security breaches. - FY2019RestatedAnnual report
「In the event of a system failure, security breach or similar incident, important information held by the company relating to the pharmaceutical development process may be lost or leaked.」
The company continues to disclose the risk of loss or leakage of development information due to system failures and security breaches. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of loss of development information due to system failures and security breaches. - FY2018RestatedAnnual report
「In the event of a system failure, security breach or similar incident, important information held by the company relating to the pharmaceutical development process may be lost or leaked.」
The company continues to disclose the risk of loss or leakage of development information due to system failures and security breaches. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of loss of development information due to system failures and security breaches. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of loss of development information due to system failures and security breaches. - FY2017First statedAnnual report
「In the event of a system failure, security breach or similar incident, important information held by the company relating to the pharmaceutical development process may be lost or leaked.」
The risk of information loss or leakage caused by viruses, unauthorized access, natural disasters, communication or power outages and other events, as well as the resulting risks of development delays and reputational damage, has been disclosed for the first time.